153 related articles for article (PubMed ID: 2893360)
21. Synthesis and dopamine receptor modulating activity of 3-substituted gamma-lactam peptidomimetics of L-prolyl-L-leucyl-glycinamide.
Dolbeare K; Pontoriero GF; Gupta SK; Mishra RK; Johnson RL
J Med Chem; 2003 Feb; 46(5):727-33. PubMed ID: 12593653
[TBL] [Abstract][Full Text] [Related]
22. Effects of cyclo (Leu-Gly) on neurochemical indices of striatal dopaminergic supersensitivity induced by prolonged haloperidol treatment.
Le Douarin C; Fage D; Scatton B
Life Sci; 1984 Jan; 34(4):393-9. PubMed ID: 6694528
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and dopamine receptor modulating activity of unsubstituted and substituted triproline analogues of L-prolyl-L-leucyl-glycinamide (PLG).
Baures PW; Pradhan A; Ojala WH; Gleason WB; Mishra RK; Johnson RL
Bioorg Med Chem Lett; 1999 Aug; 9(16):2349-52. PubMed ID: 10476867
[TBL] [Abstract][Full Text] [Related]
24. Are the pharmacological effects of L-prolyl-L-leucyl-glycinamide (PLG) mediated through specific receptor mechanisms?
Chiu S; Wong YW; Wan YP; Chiu P; Mishra RK
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):739-42. PubMed ID: 6141616
[TBL] [Abstract][Full Text] [Related]
25. Chronic ganglioside treatment counteracts the biochemical signs of dopamine receptor supersensitivity induced by chronic haloperidol treatment.
Agnati LF; Fuxe K; Benfenati F; Battistini N; Zini I; Toffano G
Neurosci Lett; 1983 Oct; 40(3):293-7. PubMed ID: 6646502
[TBL] [Abstract][Full Text] [Related]
26. Factors contributing to the up regulation of dopaminergic receptors by chronic haloperidol.
Schweitzer JW; Schwartz R; Friedhoff AJ
Res Commun Chem Pathol Pharmacol; 1982 Oct; 38(1):21-30. PubMed ID: 7146618
[TBL] [Abstract][Full Text] [Related]
27. MIF-I and postsynaptic receptor sites for dopamine.
Kostrzewa RM; Hardin JC; Snell RL; Kastin AJ; Coy DH; Bymaster F
Brain Res Bull; 1979; 4(5):657-62. PubMed ID: 39665
[TBL] [Abstract][Full Text] [Related]
28. Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
Gordon JH; Diamond BI
Biol Psychiatry; 1981 Apr; 16(4):365-71. PubMed ID: 7194695
[TBL] [Abstract][Full Text] [Related]
29. Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug.
Severson JA; Robinson HE; Simpson GM
Psychopharmacology (Berl); 1984; 84(1):115-9. PubMed ID: 6149590
[TBL] [Abstract][Full Text] [Related]
30. Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats.
Rupniak NM; Kilpatrick G; Hall MD; Jenner P; Marsden CD
Psychopharmacology (Berl); 1984; 84(4):512-9. PubMed ID: 6441952
[TBL] [Abstract][Full Text] [Related]
31. Conditional tolerance to haloperidol-induced catalepsy is not caused by striatal dopamine receptor supersensitivity.
de Graaf CJ; Korf J
Psychopharmacology (Berl); 1986; 90(1):54-7. PubMed ID: 3094062
[TBL] [Abstract][Full Text] [Related]
32. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain.
Burt DR; Creese I; Snyder SH
Science; 1977 Apr; 196(4287):326-8. PubMed ID: 847477
[TBL] [Abstract][Full Text] [Related]
33. Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia.
Sharma S; Paladino P; Gabriele J; Saeedi H; Henry P; Chang M; Mishra RK; Johnson RL
Peptides; 2003 Feb; 24(2):313-9. PubMed ID: 12668218
[TBL] [Abstract][Full Text] [Related]
34. Lithium dissociates haloperidol-induced behavioral supersensitivity from reduced dopac increase in rat striatum.
Meller E; Friedman E
Eur J Pharmacol; 1981 Nov; 76(1):25-9. PubMed ID: 7318921
[TBL] [Abstract][Full Text] [Related]
35. Influence of lithium on biochemical manifestations of striatal dopamine target cell supersensitivity induced by prolonged haloperidol treatment.
Le Douarin C; Oblin A; Fage D; Scatton B
Eur J Pharmacol; 1983 Sep; 93(1-2):55-62. PubMed ID: 6628547
[TBL] [Abstract][Full Text] [Related]
36. Modulation of high-affinity CNS dopamine D2 receptor by L-pro-L-leu-glycinamide (PLG) analogue 3(R)-(N-L-prolylamino)-2-oxo-1-pyrrolidineacetamide.
Mishra RK; Srivastava LK; Johnson RL
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):821-7. PubMed ID: 1981396
[TBL] [Abstract][Full Text] [Related]
37. [The effect of prolyl-leucyl-glycine (MIF-1) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on dopamine levels of the striatum].
Sheng JG
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1989 Aug; 22(4):213-5, 253. PubMed ID: 2575971
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide.
Baures PW; Ojala WH; Costain WJ; Ott MC; Pradhan A; Gleason WB; Mishra RK; Johnson RL
J Med Chem; 1997 Oct; 40(22):3594-600. PubMed ID: 9357526
[TBL] [Abstract][Full Text] [Related]
39. Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride.
Prosser ES; Pruthi R; Csernansky JG
Psychopharmacology (Berl); 1989; 99(1):109-16. PubMed ID: 2506596
[TBL] [Abstract][Full Text] [Related]
40. Amantadine reduces haloperidol-induced dopamine receptor hypersensitivity in the striatum.
Allen RM; Lane JD; Brauchi JT
Eur J Pharmacol; 1980 Jul; 65(2-3):313-5. PubMed ID: 7190503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
